A recent study of patients with an inoperable brain tumor found those without chromosomes 1p and 19q did better on the chemotherapy drug temozolomide, than those without the genetic abnormality.
The lack of these chromosomes actually helps people with Gliomatosis cerebri, a rare and difficult to diagnose brain tumor respond better to a new treatment and live 4 years longer than those with the chromosomes.
"Before now, we weren't sure which factors influenced how well a person with this type of brain tumor would respond to the treatment," said Dr. Marc Sanson of INSERM, the French government health agency in Paris.
Study participants underwent genetic testing and received monthly treatments of temozolomide for up to two years, resulting in 88 percent of those missing the chromosomes responding well to the drug compared with only 25 percent of those with the chromosomes.
Those afflicted with the brain tumor and the two missing chromosomes will now be treated with the chemotherapy drug temozolomide, and will survive an average of 5.5 years longer than patients with the chromosomes, without tumor growth.
Full Article: Missing Chromosomes Respond to Brain Tumor Treatment
Related Articles:
Brain Tumor Information
Miracle Drug Shrinks Brain Tumors
Chemotherapy Enhances Effectiveness of Vaccine
The lack of these chromosomes actually helps people with Gliomatosis cerebri, a rare and difficult to diagnose brain tumor respond better to a new treatment and live 4 years longer than those with the chromosomes.
"Before now, we weren't sure which factors influenced how well a person with this type of brain tumor would respond to the treatment," said Dr. Marc Sanson of INSERM, the French government health agency in Paris.
Study participants underwent genetic testing and received monthly treatments of temozolomide for up to two years, resulting in 88 percent of those missing the chromosomes responding well to the drug compared with only 25 percent of those with the chromosomes.
Those afflicted with the brain tumor and the two missing chromosomes will now be treated with the chemotherapy drug temozolomide, and will survive an average of 5.5 years longer than patients with the chromosomes, without tumor growth.
Full Article: Missing Chromosomes Respond to Brain Tumor Treatment
Related Articles:
Brain Tumor Information
Miracle Drug Shrinks Brain Tumors
Chemotherapy Enhances Effectiveness of Vaccine
No comments:
Post a Comment